StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$4.77−0.33 (-6.47%)

Close on Nov 18, 2026Market cap $218.93MP/E –Yield –

BioAge Labs operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioAge Labs's operating income for the twelve months ending Jun 30, 2026 was -$106.27M. For fiscal 2025 it was -$92.78M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$92.78M–
FY2024Dec 31, 2024-$78.19M–
FY2023Dec 31, 2023-$48.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.33M–
Q1 FY2026Mar 31, 2026-$25.38M–
Q4 FY2025Dec 31, 2025-$28.42M–
Q3 FY2025Sep 30, 2025-$23.14M–
Q2 FY2025Jun 30, 2025-$24.77M–
Q1 FY2025Mar 31, 2025-$16.45M–
Q4 FY2024Dec 31, 2024-$25.36M–
Q3 FY2024Sep 30, 2024-$24.75M–
Q2 FY2024Jun 30, 2024-$15.27M–
Q1 FY2024Mar 31, 2024-$12.81M–
Q4 FY2023Dec 31, 2023-$13.60M–
Q3 FY2023Sep 30, 2023-$9.89M–

More BioAge Labs figures

See a number that looks wrong?